Other
Double-Blind
0
Pipeline Programs↗
20
Active Trials↗
68
Companies Involved↗
Double-blind is an early-stage landscape with 0 programs across 68 companies. The most active players are AstraZeneca, Pfizer, Takeda.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
244
clinical trials
Completed178 · 73%
Terminated22 · 9%
Unknown status15 · 6%
Not yet recruiting9 · 4%
Recruiting8 · 3%
Withdrawn7 · 3%
Other5 · 2%
Clinical Trials
Trial Activity
244 trials
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
Recruiting·—·Phase 3·NCT06631287·550 enrolled
A Comparison of the Physiological and Behavioral Effects of Suvorexant and Zolpidem in Healthy Volunteers: A Randomized, Double-blind, Placebo Controlled Study
Active, not recruiting·WWalter Reed Army Institute of Research (WRAIR)·Phase 1·NCT04273776·90 enrolled
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study on the Treatment of Depression with Jieyu Chufan Capsules
Not yet recruiting·—·Phase 4·NCT06749470·480 enrolled
Preoperative Daptomycin Prophylaxis in Two-Stage Exchange Arthroplasty: A Prospective, Randomized, Double-Blinded Trial
Not yet recruiting·—·N/A·NCT06189885·184 enrolled
Page 1 of 17
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)